An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 19 Feb 2018 Planned End Date changed from 13 Jan 2020 to 31 Oct 2019.
- 19 Feb 2018 Planned primary completion date changed from 13 Jan 2020 to 31 Oct 2019.
- 08 Jun 2017 Status changed from recruiting to active, no longer recruiting.